After selling its late-stage dermatology program in May 2022, Brickell Biotech (NASDAQ:BBI) has pivoted its focus to developing differentiated therapeutics for the treatment of autoimmune, inflammatory and other...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Cantor starts Mereo BioPharma at OW; PT $4
Cantor Fitzgerald initiated coverage of Mereo BioPharma (NASDAQ:MREO) with an “overweight” rating and $4 price target. The stock closed at $1.15 on Aug. 11. Mereo is a clinical-stage biopharmaceutical company that is...
BTIG cuts Pear Therapeutics PT to $5 on Q2 results
BTIG reduced its price target for Pear Therapeutics (NASDAQ:PEAR) to $5 from $11 but maintained its “buy” rating after the company missed second quarter revenue consensus and lowered 2022 revenue guidance. The stock...
Cantor cuts TerrAscend to neutral on model update post Q2 miss
Cantor Fitzgerald downgraded TerrAscend (OTCQX:TRSSF) to “neutral” from “overweight” and reduced its price target to $2.85 from $6.45 on lower estimates and sectoral derating. The stock closed at $2.40 on Aug. 11...
SVB cuts 4D Molecular to MP on elevated risk to Fabry program
SVB Securities downgraded 4D Molecular Therapeutics (NASDAQ:FDMT) to “market perform” from “outperform” and reduced its price target to $12, citing an elevated risk to the lead Fabry disease program, along with an...
BTIG ups Acutus PT to $2.50 on Q2, strategy shift plan results
BTIG raised its price target for Acutus Medical (NASDAQ:AFIB) to $2.50 from $1.50 after the company beat consensus estimates for second quarter revenue. The stock closed at $1.66 on Aug. 11. Acutus Medical is a cardiac...
Rani Therapeutics posts positive Phase 1 results in osteoporosis
Rani Therapeutics (NASDAQ:RANI) reported positive topline results from the single-ascending dose portion of its Phase 1 clinical study of RT-102, a RaniPill capsule containing a proprietary formulation of human...
Cantor starts MindMed at OW; PT $3
Cantor Fitzgerald launched coverage of MindMed (NASDAQ:MNMD) with an “overweight” rating and price target of $3. The stock closed at 58 cents on Aug. 9. MindMed is an early-stage neuro-innovator developing psychedelic...
SAB Biotherapeutics expanding pipeline for C. diff as DoD contract winds down
SAB Biotherapeutics (NASDAQ:SABS) will be discontinuing its work with the U.S. Department of Defense (DoD) under a prototype research and development agreement. The agreement, which was awarded in the summer of 2019...
Blue Water Vaccines in $10-million private placement
Blue Water Vaccines (NASDAQ:BWV) entered into definitive agreements with several healthcare-focused institutional investors for the purchase of 3,683,280 common shares of the company in a private placement priced at-the...
Dawson James cuts Mesoblast to neutral on potential capital raise
Dawson James downgraded Mesoblast (NASDAQ:MESO; ASX:MSB) to “neutral” and removed its price target after the stock was halted on Aug. 4 in Australia with news of a proposed private placement and another notice of a halt...
Cantor cuts Galmed to neutral on limited insights into programs
Cantor Fitzgerald downgraded Galmed Pharmaceuticals (NASDAQ:GLMD) to “neutral” from “overweight” and slashed its price target to 70 cents from $5 after the company announced a business update along with financials for...
Enzo Biochem appoints Matthew Kupferberg as general counsel
Enzo Biochem (NYSE:ENZ) named Matthew Kupferberg as the company’s in-house general counsel. He was most recently general counsel, chief compliance officer and privacy officer of Digital Medical Technologies, a...
Just a few of the companies we’ve highlighted along the way
